We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Chloroquine for Influenza Prevention Trial (CHIP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01078779
Recruitment Status : Unknown
Verified February 2010 by National University Hospital, Singapore.
Recruitment status was:  Active, not recruiting
First Posted : March 2, 2010
Last Update Posted : March 2, 2010
Information provided by:

February 28, 2010
March 2, 2010
March 2, 2010
November 2009
May 2010   (Final data collection date for primary outcome measure)
Laboratory-confirmed influenza-like illness [ Time Frame: 12 weeks ]
Same as current
No Changes Posted
Serologically-confirmed influenza infection (symptomatic or asymptomatic) [ Time Frame: 12 weeks ]
Four-fold rise in influenza antibody titre at week 12 compared to the baseline sample
Same as current
Not Provided
Not Provided
The Chloroquine for Influenza Prevention Trial
A Randomised, Double-blind, Placebo Controlled Trial of Chloroquine for the Prevention of Influenza
A randomised controlled trial to determine the efficacy of chloroquine for the prevention of influenza
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Drug: Chloroquine
    Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
    Other Names:
    • Chloroquine phosphate
    • Plaquenil
  • Drug: Placebo
    Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
  • Experimental: Chloroquine
    Intervention: Drug: Chloroquine
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, Wong G, Wilder-Smith A. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011 Sep;11(9):677-83. doi: 10.1016/S1473-3099(11)70065-2. Epub 2011 May 5. Erratum in: Lancet Infect Dis. 2011 Sep;11(9):655. Smith, Annelies Wilder [corrected to Wilder-Smith, Annelies].

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
August 2010
May 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 -65
  • Have the ability to provide informed consent
  • If a woman of child-bearing potential, willing to use contraception for the period of the trial

Exclusion Criteria:

  • Acute influenza-like illness at screening
  • History of psoriasis, porphyria cutanea tarda, epilepsy, myasthenia gravis, myopathy of any cause, cardiac arrhythmias, or serious hepatic or renal disease
  • Pregnancy or breast feeding
  • Current use of medication with known serious hepatotoxic effects
  • Current use of medication with known serious interaction with CQ: amiodarone, anticonvulsants, ciclosporin, digoxin, mefloquine, moxifloxacin
  • Current severe depression (as indicated by current use of antidepressant medication)
  • Known serious retinal disease
  • Current or recent (within the past 30 days) participation in any other clinical intervention trial.
  • Known G6PD deficiency
  • Vaccination for influenza (seasonal or H1N1 strain) within the 3 months prior to screening
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Professor Nicholas Paton, National University of Singapore
National University Hospital, Singapore
Not Provided
Study Chair: Nicholas I Paton, MD FRCP National University, Singapore
Principal Investigator: Lawrence Lee, MD PhD National University, Singapore
National University Hospital, Singapore
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP